Market closed
BiomX Inc./$PHGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BiomX Inc.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Ticker
$PHGE
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Ness Ziona, Israel
Employees
55
ISIN
US09090D3017
Website
BiomX Inc. Metrics
BasicAdvanced
$13M
-
-$3.36
1.32
-
Price and volume
Market cap
$13M
Beta
1.32
52-week high
$0.77
52-week low
$0.48
Average daily volume
122K
Financial strength
Current ratio
2.482
Quick ratio
2.039
Long term debt to equity
35.009
Total debt to equity
39.689
Interest coverage (TTM)
-41.74%
Management effectiveness
Return on assets (TTM)
-65.10%
Return on equity (TTM)
-130.21%
Valuation
Price to book
1.77
Price to tangible book (TTM)
1.77
Price to free cash flow (TTM)
-0.174
Growth
Earnings per share change (TTM)
-34.06%
3-year earnings per share growth (CAGR)
-37.73%
BiomX Inc. News
AllArticlesVideos
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
GlobeNewsWire·6 days ago
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
GlobeNewsWire·1 month ago
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BiomX Inc. stock?
BiomX Inc. (PHGE) has a market cap of $13M as of May 14, 2025.
What is the P/E ratio for BiomX Inc. stock?
The price to earnings (P/E) ratio for BiomX Inc. (PHGE) stock is 0 as of May 14, 2025.
Does BiomX Inc. stock pay dividends?
No, BiomX Inc. (PHGE) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next BiomX Inc. dividend payment date?
BiomX Inc. (PHGE) stock does not pay dividends to its shareholders.
What is the beta indicator for BiomX Inc.?
BiomX Inc. (PHGE) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.